Aptus Pharma Ltd
Aptus Pharma Q2 Results 2026 (FY27): Capex ₹35 Cr
Q2 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #36 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q2 FY27 call signalled
3 of 4 strong
The short version
Aptus Pharma aims for rapid growth transitioning from a local to a national pharmaceutical player by 2029. Aptus Pharma is focused on expanding from a regional to a national player by 2029 with a pan-India presence. - The company plans to strengthen its acute and chronic therapy portfolio and expand OTC and wellness products. - Manufacturing expansion is targeted by March 2028, with 20% of the product portfolio to be produced in-house. - Revenue from operations grew significantly in H1 FY 2027 to Rs.
From Aptus Pharma Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
Revenue & Sales Performance
- Aptus Pharma aims for rapid growth transitioning from a local to a national pharmaceutical player by 2029.
- Targeting 46% geographic coverage across India by March 2027, with plans to reach pan-India presence by 2029.
- Focus on expanding core prescription business, acute and chronic therapy portfolios, OTC and wellness segments.
- Manufacturing expansion planned by March 2028 to produce approximately 20% of product portfolio in-house, enhancing supply control.
- International expansion is a strategic goal with selective markets in Asia, Africa, and Latin America being evaluated.
- Expected growth is supported by an increasing distributor network (250+ distributors), product portfolio of 300+ formulations, and retail presence in 45,000+ outlets.
2 more points from Aptus Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aptus Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Aptus Pharma plans a manufacturing expansion with an initial CAPEX of approximately ₹35 crore.
- Out of this, around ₹25 crore will be funded through a preferential issue.
- The manufacturing facility will focus on producing about 20% of their product portfolio for self-consumption, with the remaining capacity aimed at exports to Rest of the World (ROW) countries.
- The CAPEX project is expected to be commissioned progressively, with the initial phase planned around March 2028.
- The company aims to strengthen its manufacturing capabilities to support supply chain efficiency, product availability, and brand portfolio control.
2 more points from Aptus Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aptus Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Aptus Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Continue your research
What Aptus Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL
- Lyka Labs Ltd (Q2 FY27)
Year-on-Year revenue growth for the quarter: approximately 104.5% increase (8,650.89 vs 4,230.94 lakhs). Key results statement takeaways from Lyka Labs Ltd's Q2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aptus Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aptus Pharma Ltd Q2 FY27 results?
Aptus Pharma aims for rapid growth transitioning from a local to a national pharmaceutical player by 2029. Aptus Pharma is focused on expanding from a regional to a national player by 2029 with a pan-India presence. - The company plans to strengthen its acute and chronic therapy portfolio and expand OTC and wellness products. - Manufacturing expansion is targeted by March 2028, with 20% of the product portfolio to be produced in-house. - Revenue from operations grew significantly in H1 FY 2027 to Rs.
What is Aptus Pharma Ltd share price analysis?
Aptus Pharma Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 171.7 with a market cap of ₹793 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aptus Pharma Ltd planning capital expenditure?
Aptus Pharma plans a manufacturing expansion with an initial CAPEX of approximately ₹35 crore.
Keep Aptus Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.